Jiangsu Jibeier Pharmaceutical Co., Ltd. (SHSE: 688566)
Health Care · Pharmaceuticals · CN
CN¥27.46
-0.94% today · -17.3% 1Y
Jiangsu Jibeier Pharmaceutical Co., Ltd. (SHSE: 688566) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $824.45M and employs 1,380 people.
Over the last twelve months the share price has lost 17.3%, trading between 22.82 and 35.96.
Tweenvest scores Jiangsu Jibeier Pharmaceutical Co., Ltd. across four factors: quality 87/100, value 44/100, growth 71/100, dividend 62/100. Its strongest factor is quality.
688566 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $824.45M
- Revenue (TTM)
- $147.32M
- P/E
- 25.88
- EPS
- 1.06
- Dividend yield
- 1.89%
- Beta (5Y)
- 0.27
- 52-week high
- CN¥35.96
- 52-week low
- CN¥22.82
- Avg volume (3M)
- —
- Shares outstanding
- 201.10M
- Employees
- 1,380
- Next earnings
- —
About Jiangsu Jibeier Pharmaceutical Co., Ltd.
Jiangsu Jibeier Pharmaceutical Co., Ltd. is a pharmaceutical enterprise based in Zhenjiang, China, established in 2001. The company's core operations involve the research, development, manufacturing, and sales of a diverse range of pharmaceutical products, including chemical preparations, traditional Chinese medicine formulations, and active pharmaceutical ingredients (APIs). Its product portfolio addresses various health concerns, offering solutions for boosting white blood cell counts, enhancing the immune system, treating joint-related ailments, managing high blood pressure, combating ocular infections, alleviating bronchitis symptoms, and protecting liver function, among others. Additionally, Jiangsu Jibeier is actively engaged in developing new therapeutic drugs, with its pipeline focusing on treatments for conditions such as depression, oncology (tumors), and gastrointestinal disorders.
- ISIN
- CNE100004041
- Founded
- 2001
- Listed since
- May 18, 2020
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Shanghai Kaibao Pharmaceutical CO.,LtdSZSE: 300039 | $841.72M | CN¥5.39 | +1.70% |
| HK inno.N CorporationKOSDAQ: A195940 | $836.59M | ₩39,700.00 | -1.12% |
| SpyGlass Pharma, Inc.NasdaqGS: SGP | $833.52M | $25.08 | +0.64% |
| Hunan Jiudian Pharmaceutical Co., Ltd.SZSE: 300705 | $828.42M | CN¥11.23 | +2.93% |
| China Traditional Chinese Medicine Holdings Co. LimitedSEHK: 570 | $814.96M | HK$1.27 | +3.25% |
| Sichuan Goldstone Asia Pharmaceutical Inc.SZSE: 300434 | $807.31M | CN¥13.46 | +4.18% |
| Aarti Pharmalabs LimitedNSEI: AARTIPHARM | $801.57M | Rs855.50 | -11.67% |
| Beijing Beilu Pharmaceutical Co., Ltd.SZSE: 300016 | $795.49M | CN¥9.16 | -4.18% |
Figures last refreshed Oct 11, 2026.